Ocriplasmin for Treatment for Symptomatic Vitreomacular Adhesion Including Macular Hole

Inclusion Criteria: * Subjects 18 years of age or older and of either gender * Presence of vitreomacular adhesion * Best corrected visual acuity (BCVA) of 20/32 or worse in study eye * BCVA of 20/800 or better in the non-study eye Exclusion Criteria: * History or current evidence of proliferative retinopathy, exudative age-related macular degeneration (AMD) or retinal vein occlusion in the study eye * Any vitreous hemorrhage or any other vitreous opacification which precludes the visualization of the posterior pole by visual inspection OR adequate assessment of the macula by spectral-domain optical coherence tomography (SD-OCT) in the study eye * Macular hole of \> 400 µm diameter in the study eye * Presence of epiretinal membrane (ERM) * Aphakia in the study eye * High myopia (more than 8D) in study eye * History of rhegmatogenous retinal detachment in either eye * History of vitrectomy in the study eye * Previous participation in this trial or prior administration of ocriplasmin in the study eye